Anti-Apoptosis Effect of Astragaloside Iv on Alzheimer's Disease Rat Model via Enhancing the Expression of Bcl-2 And Bcl-Xl

  • You Yin Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Yan Liu Department of Pharmacy, Xinhua Hospital, affiliated to Shanghai Jiaotong University
  • Liuqing Huang Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Shuqi Huang Department of Neurology, Changzheng Hospital of Second Military Medical University
  • JianHua Zhuang Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Xiaoyan Chen Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Lin Zhang Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Huijuan Wu Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Fuyuan Shao Department of Neurology, Changzheng Hospital of Second Military Medical University
  • Zhongxin Zheo Department of Neurology, Changzheng Hospital of Second Military Medical University

Abstract

The aim is to explore the protective effect of Astragaloside IV on Alzheimer’s disease (AD) in rats induced  by amyloid-ß peptide (Aß1-42) and its potential therapeutic mechanism. Methods: 50 Male Sprague Dawley  rats were divided into five groups (10 rats for each): control group, model group, treatment groups 1~3.  10μg Aß1-42 was injected bilaterally into the dorsal dentate gyrus of the hippocampus of rats in the model  and treatment groups to prepare the AD models. 24h after modeling, Astragaloside IV administration, with  different drug dosages of 20mg/(kg•day), 40mg/(kg•day) and 60mg/(kg•day), was performed by gastric  perfusion for rats in the treatment group 1~3. Later on, the cognitive ability of rats was examined by a series  of behavioral tests, and the expression of Bcl-2 and Bcl-xl in the hippocampus of rats was detected by the  fluorescein based Quantitative RT-PCR. Results: The spontaneous alternation test in a Y maze and Morris  water maze task have demonstrated that the repeated daily administration of Astragaloside IV at the doses  of 20mg/kg bw/day) (p<0.05), 40mg/kg bw/day) (p<0.01), and 60mg/kg bw/day) (p<0.01) significantly  ameliorated the impairment of performance caused by Aß1–42. Furthermore, Astragaloside IV also enhanced  the expression of Bcl-2 and Bcl-xl in hippocampal neurons of rats in a dosage-dependent manner. Conclusion:  These findings suggest that Astragaloside IV could alleviate cognitive impairment and enhance the  expression of Bcl-2 and Bcl-xl in hippocampus of rat models with AD. 

Section
Articles